Nvidia: AI Leader Trading at an Attractive Valuation
July 1, 2025 Where to Rent Stable Turkish Datacenter Proxies?
June 24, 2025 PayPal’s News Analysis—A Short and Medium-Term Price Forecast
June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
Teva (TEVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: July 9, 2025 (18:35)
Sector: HealthcareThe share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now
News Impact Analyzer
Full report
This Week
|
Na | Impact: Na | News: Na |
Previous Week
|
Na | Impact: Na | News: Na |
Two Weeks Ago
|
Na | Impact: Na | News: Na |
Three Weeks Ago
|
Bullish | Impact: 5 | News: 2 (1/1/0) |
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 1 (1/0/0) |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Bullish | Opinions: 1 (1/0/0) |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important TEVA news

Generic Drugmakers Tread Carefully as Trump Pushes for U.S. Manufacturing


Teva Joins Forces with Fosun to Target Cancer Treatment Market with TEV-56278


Goldman Praises Teva: Bullish Outlook with $24 Target

Historical and forecast chart of Teva stock
The chart below shows the historical price of Teva stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Teva stock price can be found in the table below.
Long-term forecasts by years.
Teva Pharmaceutical Industries Lim. (TEVA) Analysts predictions review

Teva Pharmaceuticals shows potential for gradual recovery driven by a pivot to higher-margin biosimilars and specialty medicines, alongside operational efficiency and deleveraging efforts. These strategies enhance profitability and reduce risk. While the company's branded portfolio supports growth, challenges such as declining generics performance, legal risks from opioid litigation, and regulatory headwinds like the IRA may weigh on near-term results. Macroeconomic factors, including interest rates and currency fluctuations, also pose uncertainties. Successful execution of strategic initiatives will be key to sustaining investor confidence and improving long-term performance.

Teva Pharmaceuticals: Balancing Growth Opportunities Amid Regional Uncertainty

Teva Pharmaceuticals' financial performance is heavily influenced by its ability to navigate regional risks, including political instability in key operational areas. The author's analysis asserts that while these factors present challenges, they are counterbalanced by the company's disciplined focus on operational efficiency and cost optimization, which are crucial for maintaining margins given the near-term economic pressures.
Growth Drivers and Headwinds
Another significant factor highlighted is Teva's commitment to diversifying its product pipeline, with a specific emphasis on biosimilars and specialty medicines. The successful execution of this strategy could provide a sustainable growth trajectory, as these segments offer higher margins compared to generics, positioning the company as a stronger player in the pharmaceutical market.
Further, Teva's ongoing deleveraging efforts were identified as a positive catalyst for the stock. By reducing debt levels, the company not only stabilizes its financial position but also improves its appeal to investors seeking reduced risk profiles. This could have a medium- to long-term positive impact on the stock price.
The author's perspective suggests that macroeconomic headwinds, particularly fluctuating interest rates and currency risks, remain an overhang on the stock. However, the company's effective risk management strategies and strong fundamentals mitigate the potential downside, solidifying its investment appeal despite these challenges.

Teva Pharmaceuticals: Poised for Recovery and Investment Upside

Teva Pharmaceuticals is undergoing a strategic transformation with several factors aligning to potentially strengthen its stock performance. The company has focused on diversifying its product portfolio, prioritizing higher-margin assets such as biosimilars and innovative treatments, which may significantly enhance its profitability. Analyst Array notes that this shift signals Teva’s commitment to counteract reliance on generic drugs, historically affected by intense pricing competition.
Key Drivers in Teva’s Turnaround Strategy
Teva has also made significant strides in operational efficiency, reducing its overall debt burden through disciplined expense management and asset optimization. This reduction not only improves its balance sheet strength but also positions the company to channel resources into future growth initiatives, which is a net positive for investor sentiment. Furthermore, its leadership appears determined to lead new initiatives that target core therapeutic areas like neurology and immunology, leveraging recent approvals and partnerships.
The company's legal challenges, particularly those involving opioid litigation uncertainties, remain a critical risk factor. According to Array, while potential settlements could weigh on short-term performance, their resolution may act as a long-term catalyst for improved investor confidence. Additionally, Array emphasizes that macroeconomic pressures such as fluctuating currency rates in key markets—although manageable—may influence near-term volatility. Overall, Teva seems positioned for a gradual but noteworthy recovery, assuming it successfully delivers on these key initiatives.

Teva: Navigating Strong Brand Growth Amid Generic Pressures and Policy Challenges

Teva's ongoing momentum in its branded drug portfolio is a critical pillar of its growth strategy, with innovative therapies demonstrating robust demand. This development reflects positively on the company's ability to pivot towards high-margin specialty pharmaceuticals, fostering greater revenue resilience.
Balancing Growth Drivers and Risks in Teva's Outlook
Conversely, the continued decline in the generic drug segment underscores structural challenges, such as pricing pressure and competition, which weigh on the company's topline. These headwinds could erode profitability further if offset strategies are not effectively implemented.
Additionally, regulatory headwinds, particularly from the Inflation Reduction Act (IRA), present notable risks to long-term revenue. The potential impact of pricing reforms and government negotiations on Teva's product portfolio could dampen earnings, especially if the company remains overly reliant on affected segments.
TEVA Pharmaceuticals stands at a critical juncture within the immunology sector, benefiting from its diversified portfolio and a solid pipeline of drug development. Its position as a major player in the generic drugs market continues to provide the company with a cash flow safety net, enabling long-term investments in innovative treatments. However, intense competition in both generics and specialty drugs remains a notable pressure point for margins.
Growth Drivers and Challenges for TEVA
TEVA's recent focus on expanding its immunology offerings reflects a strategic pivot towards high-margin specialty drugs to counteract ongoing pricing struggles in the generics segment. This shift is likely to bolster revenue growth in the medium to long term if clinical trials and regulatory approvals proceed as planned. Additionally, the company's cost optimization measures, including facility consolidations and operating expense reductions, signal improved efficiency and profitability potential, which investors will closely monitor for tangible results in quarterly earnings.
On the downside, ongoing legal liabilities from opioid-related settlements present a recurring headwind for TEVA, adding uncertainty to future cash flow allocations. Moreover, foreign exchange volatility, given its significant international footprint, could further pressure earnings in the near term.
The author underscores that while TEVA exhibits significant long-term potential tied to its R&D efforts and market pivots, near-term risks warrant a cautious approach. Investors seeking exposure should weigh these opportunities against the risks of delayed regulatory approvals and macroeconomic challenges.
Teva Pharmaceuticals' strategic focus on Duvakitug, a novel pharmaceutical product, highlights the company's efforts to revitalize its growth trajectory amidst a challenging competitive landscape. The drug is positioned as a potential breakthrough in its therapeutic category, potentially driving meaningful revenue growth if it gains strong market adoption and regulatory support. The author emphasizes the significance of this pipeline asset, underscoring its role in boosting confidence in Teva's innovation capabilities and long-term value.
Macroeconomic Environment and Operational Challenges
Broader macroeconomic conditions, including inflationary pressures and global supply chain disruptions, remain critical challenges for Teva. These factors could compress margins and slow operational recovery, especially as the company continues its debt-reduction efforts. The author also notes increased competition in the generics market, which may dampen price growth and offset revenue gains from innovative products like Duvakitug.
Cost management initiatives and restructuring measures are additional levers influencing Teva’s financial health. While these actions may enhance operational efficiency, they are not without execution risks that could delay the realization of cost savings. Furthermore, litigation risks stemming from opioid-related settlements could weigh on investor sentiment and potentially impact near-term stock performance.
TEVA's performance is strongly influenced by its ongoing restructuring efforts aimed at reducing debt and improving operational efficiency. These initiatives are crucial in restoring investor confidence, but their impact may take time to reflect materially on the stock price, limiting near-term upside potential.
Market conditions remain a key determinant of TEVA's trajectory, with generic drug pricing pressures and competitive dynamics continuing to challenge growth. The author's analysis highlights that overcoming these external headwinds will require more strategic product launches and a focus on innovative therapies.
Debt Levels and Pipeline Strategy
The company's high debt levels, though being reduced incrementally, still pose a significant risk to its financial flexibility. Addressing this concern while simultaneously investing in R&D is critical for TEVA’s ability to remain competitive in a rapidly evolving industry.
The pipeline remains a mixed bag, offering opportunities for upside through specialty drugs while underscoring the need to accelerate innovation. Success in this area will likely dictate the company’s medium- to long-term stock performance.
Teva's operational fundamentals have shown significant improvement, particularly through its consistent focus on debt reduction and cost efficiencies. These actions signal strong financial discipline that enhances long-term sustainability, though they may have minimal immediate impact on driving the stock price higher in the near term.
Valuation and Growth Outlook
The author's analysis suggests that Teva's current valuation aligns with its improving fundamentals, reducing the likelihood of it being an undervalued opportunity. This equilibrium limits substantial upside potential unless new growth catalysts emerge or sector-wide sentiment improves.
Additionally, short-term headwinds, such as ongoing legal challenges and competition in generic drugs, remain key risks restraining price momentum. These elements weigh on investor confidence and have the potential to maintain pressure on the stock's near-term performance.
Teva Pharmaceuticals is capitalizing on its position as a leading generic drug manufacturer, which continues to drive stable revenue, particularly amidst rising demand for cost-effective healthcare solutions. The company’s dominance in generics insulates it against major competitive pressures, enhancing its allure as a long-term investment.
Leveraging Financial Discipline and Growth Prospects
Teva’s proactive debt reduction strategy has significantly strengthened its balance sheet, lowering financial risk and enhancing its capacity to reinvest in core operations. The removal of onerous financial obligations improves investor sentiment and positions the company for better forward-looking profitability.
Growth indicators, including new product launches and strategic market expansions, highlight management’s focus on innovation and operational efficiency. These developments provide tailwinds for revenue acceleration and improved market positioning in the near to medium term.
Finally, macroeconomic factors such as inflationary pressures and global healthcare trends are likely to favor Teva’s cost-effective drug offerings. As governments and insurers push for reduced healthcare expenditures, Teva is well-placed to benefit from elevated demand in key markets.
Comprehensive Analysis of Teva (TEVA) Stock Market Performance
Our multifaceted analysis of Teva 's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Teva stock?
- When should I record a loss on Teva stock?
- What are analysts' forecasts for Teva stock?
- What is the future of Teva stock?
We forecast Teva stock performance using neural networks based on historical data on Teva stocks.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.
Teva Pharmaceutical Industries Lim. (TEVA) News influencing stock rates

As of now, Panda has combed through 2 news items directly related to TEVA from the last 30 days. Out of these, 1 clearly showcase a bullish trend, while 0 display bearish tendencies, and 1 events are neutral.
Based on an analysis of the most important news from the last 30 days affecting TEVA shares, it's clear that bullish sentiments are completely overshadowing bearish ones. The impact of positive news is more than five times as dominant as that of negative developments.
The news analyzed fell within the period from Jun 16, 2025, to Jun 17, 2025.
Teva Streamlines Debt with Strategic Tender Offers


Teva's Strategic Growth: Truist Upgrades to Buy Ahead of Innovation Day


Teva Upsizes Senior Notes Offering to $2.3B: A Strategic Financial Move


Teva Gains Momentum with Upgraded Margin Clarity Through J.P. Morgan


Teva's $2.5B Austedo Ambition Fuels Positive Growth Momentum


Teva Stocks Climb Despite Q1 Revenue Miss Due to Forex Challenges


Teva Misses Full-Year Revenue Guidance Despite Q1 Gains


Teva Pharmaceutical Q1 2025 Earnings: Expectations Set at $0.46 EPS Amid Revenue Growth


Viatris Loses EU Authorization for Generic Cancer Drug, Boosting Teva's Trisenox


Teva and Alvotech Secure FDA Approval for Biosimilar to Blockbuster Stelara


Teva daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul 11 | 16.61 | 16.06 | 17.31 | 7.82 |
Jul 12 | 16.17 | 15.44 | 16.94 | 9.67 |
Jul 13 | 16.52 | 15.74 | 16.82 | 6.80 |
Jul 14 | 15.64 | 15.37 | 16.26 | 5.74 |
Jul 15 | 15.30 | 14.57 | 15.59 | 6.99 |
Jul 16 | 15.67 | 14.92 | 16.17 | 8.38 |
Jul 17 | 15.87 | 15.21 | 16.63 | 9.33 |
Jul 18 | 15.45 | 15.15 | 16.04 | 5.88 |
Jul 19 | 15.09 | 14.78 | 15.49 | 4.78 |
Jul 20 | 14.81 | 14.27 | 14.99 | 5.04 |
Jul 21 | 14.58 | 14.35 | 15.16 | 5.61 |
Jul 22 | 15.17 | 14.51 | 15.57 | 7.27 |
Jul 23 | 15.75 | 15.16 | 16.35 | 7.85 |
Jul 24 | 15.41 | 14.73 | 15.61 | 5.96 |
Jul 25 | 15.08 | 14.70 | 15.55 | 5.79 |
Jul 26 | 15.73 | 15.10 | 16.23 | 7.43 |
Jul 27 | 15.73 | 14.99 | 15.94 | 6.36 |
Jul 28 | 15.93 | 15.39 | 16.63 | 8.08 |
Jul 29 | 15.21 | 14.63 | 15.55 | 6.30 |
Jul 30 | 14.38 | 14.19 | 14.95 | 5.35 |
Jul 31 | 14.47 | 14.19 | 14.86 | 4.71 |
Aug 01 | 14.54 | 14.04 | 15.02 | 7.02 |
Aug 02 | 14.94 | 14.75 | 15.14 | 2.61 |
Aug 03 | 15.25 | 14.83 | 15.85 | 6.91 |
Aug 04 | 15.51 | 15.24 | 16.16 | 5.98 |
Aug 05 | 15.19 | 14.77 | 15.91 | 7.71 |
Aug 06 | 15.61 | 15.33 | 16.09 | 4.95 |
Aug 07 | 15.90 | 15.22 | 16.21 | 6.52 |
Aug 08 | 15.42 | 14.68 | 15.98 | 8.89 |
Aug 09 | 14.78 | 14.57 | 15.17 | 4.14 |
Teva Daily Price Targets
Teva Stock Forecast 07-11-2025.
Forecast target price for 07-11-2025: $16.61.
Negative dynamics for Teva shares will prevail with possible volatility of 7.251%.
Pessimistic target level: 16.06
Optimistic target level: 17.31
Teva Stock Forecast 07-12-2025.
Forecast target price for 07-12-2025: $16.17.
Negative dynamics for Teva shares will prevail with possible volatility of 8.821%.
Pessimistic target level: 15.44
Optimistic target level: 16.94
Teva Stock Forecast 07-13-2025.
Forecast target price for 07-13-2025: $16.52.
Positive dynamics for Teva shares will prevail with possible volatility of 6.365%.
Pessimistic target level: 15.74
Optimistic target level: 16.82
Teva Stock Forecast 07-14-2025.
Forecast target price for 07-14-2025: $15.64.
Negative dynamics for Teva shares will prevail with possible volatility of 5.425%.
Pessimistic target level: 15.37
Optimistic target level: 16.26
Teva Stock Forecast 07-15-2025.
Forecast target price for 07-15-2025: $15.30.
Negative dynamics for Teva shares will prevail with possible volatility of 6.534%.
Pessimistic target level: 14.57
Optimistic target level: 15.59
Teva Stock Forecast 07-16-2025.
Forecast target price for 07-16-2025: $15.67.
Positive dynamics for Teva shares will prevail with possible volatility of 7.734%.
Pessimistic target level: 14.92
Optimistic target level: 16.17
TEVA (TEVA) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul. | 19.19 | 17.81 | 20.11 | 11.45 |
Aug. | 18.15 | 16.49 | 18.82 | 12.35 |
Sep. | 16.78 | 14.98 | 17.46 | 14.15 |
Oct. | 17.83 | 17.26 | 18.74 | 7.91 |
Nov. | 17.95 | 16.77 | 19.30 | 13.10 |
Dec. | 19.84 | 18.60 | 21.17 | 12.14 |
Teva forecast for this year
Teva Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $19.1931. Pessimistic: $17.81. Optimistic: $20.11
Teva Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $18.149. Pessimistic: $16.49. Optimistic: $18.82
Teva Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $16.7842. Pessimistic: $14.98. Optimistic: $17.46
Teva Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $17.8315. Pessimistic: $17.26. Optimistic: $18.74
Teva Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $17.9457. Pessimistic: $16.77. Optimistic: $19.30
Teva Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $19.8407. Pessimistic: $18.60. Optimistic: $21.17
Teva (TEVA) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 21.90 | 20.61 | 24.01 | 14.16 |
Feb | 20.50 | 19.68 | 21.16 | 6.98 |
Mar | 19.91 | 17.62 | 21.31 | 17.34 |
Apr | 20.49 | 18.98 | 22.12 | 14.22 |
May | 17.96 | 15.81 | 19.71 | 19.83 |
Jun | 15.26 | 13.55 | 16.09 | 15.78 |
Jul | 16.48 | 15.72 | 17.72 | 11.31 |
Aug | 16.88 | 15.72 | 18.58 | 15.41 |
Sep | 17.31 | 15.65 | 18.47 | 15.29 |
Oct | 16.75 | 16.16 | 18.90 | 14.47 |
Nov | 15.76 | 13.97 | 17.07 | 18.17 |
Dec | 16.52 | 15.04 | 18.11 | 16.93 |
Teva (TEVA) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 18.24 | 16.14 | 19.17 | 15.83 |
Feb | 15.35 | 13.63 | 16.77 | 18.74 |
Mar | 13.24 | 11.63 | 13.89 | 16.31 |
Apr | 13.36 | 11.70 | 14.77 | 20.84 |
May | 11.63 | 11.17 | 12.58 | 11.24 |
Jun | 12.34 | 11.67 | 12.85 | 9.22 |
Jul | 13.64 | 12.18 | 14.91 | 18.30 |
Aug | 13.75 | 12.26 | 15.25 | 19.62 |
Sep | 15.89 | 15.33 | 16.52 | 7.23 |
Oct | 15.15 | 13.35 | 17.09 | 21.84 |
Nov | 16.29 | 15.74 | 17.75 | 11.31 |
Dec | 15.19 | 14.00 | 16.31 | 14.16 |
Teva information and performance
5 BAZEL ST, P O B 3190, PETACH TIKVA, IL
Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.
EBITDA of Teva is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Teva (TEVA) stock dividend
Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Teva Stock)
Should I Buy Teva Shares in 2025 year?
Does Teva pay dividends?
Which economic sector do Teva 's shares belong to?
Which other securities belong to the same sector as Teva 's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.